Wegovy maker Novo Nordisk filed for U.S. FDA approval of CagriSema, a once-weekly shot that combines two compounds to treat ...

As of February 2025, the semaglutide injection (Ozempic, Wegovy) shortage was resolved. As a result, compounded semaglutide ...

Eli Lilly also said it has filed for Food and Drug Administration approval of the daily GLP-1 pill, called orforglipron, for ...

The diabetes medication semaglutide has recently become a trendy weight loss treatment. But like every drug, there are ...

Eli Lilly seeks FDA approval for orforglipron, a once-daily pill shown in trials to help maintain weight loss after stopping ...

Eli Lilly reports Phase 3 data showing oral obesity drug orforglipron maintained weight loss after Wegovy or Zepbound, beating placebo.

Eli Lilly has shown patients maintained most of their weight loss after switching from injectable GLP-1s to its oral drug ...

Topline results from the ATTAIN-MAINTAIN trial show that orforglipron, an investigational oral GLP-1 RA, helps people ...

Orforglipron helped keep weight down when used after initial therapy with an injectable, a new treatment strategy that could ...

This follows recent successful efforts by the Trump administration to cut the price of this compound for certain patients. Semaglutide is Novo Nordisk's largest growth driver, and it has not performed ...

Eli Lilly's oral pill, orforglipron, helped maintain weight loss in patients switching from injectable versions of GLP-1 ...

Medicare enrollees will save more than 50% on out-of-pocket costs for 10 common prescription drugs under their insurance ...